Guardant Health says it is the first blood test approved by the FDA as a primary screening option for colorectal cancer. Shield is also the first blood test for colorectal cancer screening that meets ...
Streamlined access to Guardant Shield ™ will help millions of people residing in senior living facilities to stay up to date on colorectal cancer screening LabFlorida/SunDX will provide patients in ...
FDA Advisory Panel Supports Approval Of Guardant Health's Blood Test For Colorectal Cancer Screening
FDA panel voted favorably that there is reasonable assurance Shield is safe, effective, and outweigh its risks. The FDA is expected to decide whether to approve Shield later this year. Get ahead of ...
July 29 (Reuters) - Guardant Health (GH.O), opens new tab said its blood test to detect cancer that starts in the colon or rectum got an approval from the U.S. Food and Drug Administration, with the ...
Guardant Health (GH) “announced new real-world data published in Current Medical Research and Opinion finding that the Shield blood-based screening test demonstrates patient adherence of 95% in ...
Colorectal cancer is the second-leading cause of cancer-related death in the U.S., even though it is highly treatable if caught early.2 The American Cancer Society estimates that more than 150,000 ...
FDA approval of a Guardant Health blood test that screens for colorectal cancer makes it the first liquid biopsy approved for this type of cancer, clearing the way to make this test more accessible to ...
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield blood test for colorectal cancer (CRC) screening has been named ...
Guardant Health delivered extremely robust Q3 results and raised full-year guidance, with Reveal and Shield beginning to make material contributions. Guardant's therapy selection and biopharma ...
Hosted on MSN
Guardant Health Stock Soars 21% After-Hours As Strong Q3, Raised Guidance Spark Retail Frenzy
・Guardant Health’s Q3 revenue surged 39% year-over-year to $265.2 million, led by strong growth in its oncology, screening, and biopharma segments. ・The company raised its 2025 revenue guidance to as ...
Guardant Health handily beat Q1 expectations and meaningfully increased full-year growth expectations. Guardant also continues to benefit from positive developments in relation to pricing, regulatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback